Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms

Overview

Journal Microorganisms

Specialty Microbiology

Date 2020 Feb 6

PMID 32019171

Citations 13

Authors

Despoina Koulenti

Elena Xu

Andrew Song

Isaac Yin Sum Mok

Drosos E Karageorgopoulos

Apostolos Armaganidis

Sotirios Tsiodras

Jeffrey Lipman

Affiliations

Soon will be listed here.

Abstract

Antimicrobial agents are currently the mainstay of treatment for bacterial infections worldwide. However, due to the increased use of antimicrobials in both human and animal medicine, pathogens have now evolved to possess high levels of multi-drug resistance, leading to the persistence and spread of difficult-to-treat infections. Several current antibacterial agents active against Gram-positive bacteria will be rendered useless in the face of increasing resistance rates. There are several emerging antibiotics under development, some of which have been shown to be more effective with an improved safety profile than current treatment regimens against Gram-positive bacteria. We will extensively discuss these antibiotics under clinical development (phase I-III clinical trials) to combat Gram-positive bacteria, such as , and . We will delve into the mechanism of actions, microbiological spectrum, and, where available, the pharmacokinetics, safety profile, and efficacy of these drugs, aiming to provide a comprehensive review to the involved stakeholders.

Citing Articles

Emergence of lineage ST150 and linezolid resistance in : a molecular epidemiology study of UTIs in Tehran, Iran.

Seyedolmohadesin M, Kouhzad M, Gotz F, Ashkani M, Aminzadeh S, Bostanghadiri N Front Microbiol. 2024; 15:1464691.

PMID: 39469459 PMC: 11514486. DOI: 10.3389/fmicb.2024.1464691.

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria.

Zheng J, Liu X, Xiong Y, Meng Q, Li P, Zhang F Emerg Microbes Infect. 2024; 13(1):2321981.

PMID: 38422452 PMC: 10906134. DOI: 10.1080/22221751.2024.2321981.

Treatment of MRSA Infection: Where are We?.

Nazli A, Tao W, You H, He X, He Y Curr Med Chem. 2024; 31(28):4425-4460.

PMID: 38310393 DOI: 10.2174/0109298673249381231130111352.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin.

Mehta Y, Mishra K, Paliwal Y, Rangappa P, Sinha S, Bhapkar S Crit Care Res Pract. 2023; 2022:2668199.

PMID: 36785544 PMC: 9922174. DOI: 10.1155/2022/2668199.

References

Holland T, ORiordan W, McManus A, Shin E, Borghei A, File Jr T . A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to.... Antimicrob Agents Chemother. 2018; 62(5). PMC: 5923167. DOI: 10.1128/AAC.02580-17. View

Koga T, Abe T, Inoue H, Takenouchi T, Kitayama A, Yoshida T . In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother. 2005; 49(8):3239-50. PMC: 1196225. DOI: 10.1128/AAC.49.8.3239-3250.2005. View

Rodvold K, Gotfried M, Chugh R, Gupta M, Yeole R, Patel A . Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. Antimicrob Agents Chemother. 2017; 62(3). PMC: 5826115. DOI: 10.1128/AAC.02297-17. View

Morrow B, Abbanat D, Baum E, Crespo-Carbone S, Davies T, He W . Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011; 55(12):5512-21. PMC: 3232800. DOI: 10.1128/AAC.00470-11. View

Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B . A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers. Antimicrob Agents Chemother. 2017; 61(5). PMC: 5404516. DOI: 10.1128/AAC.02385-16. View

English M, Fredericks C, Milanesio N, Rohowsky N, Xu Z, Jenta T . Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother. 2012; 56(4):2037-47. PMC: 3318370. DOI: 10.1128/AAC.05596-11. View

Kaplan N, Garner C, Hafkin B . AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur J Pharm Sci. 2013; 50(3-4):440-6. DOI: 10.1016/j.ejps.2013.08.019. View

Bhaduri S, Ranjan N, Arya D . An overview of recent advances in duplex DNA recognition by small molecules. Beilstein J Org Chem. 2018; 14:1051-1086. PMC: 6009268. DOI: 10.3762/bjoc.14.93. View

Mehta S, Das M, Laxmeshwar C, Jonckheere S, Thi S, Isaakidis P . Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India. PLoS One. 2016; 11(9):e0162138. PMC: 5017632. DOI: 10.1371/journal.pone.0162138. View

10.

Han H, Kim S, Shin K, Lim C, Lim K, Yu K . Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet. Curr Med Res Opin. 2013; 29(10):1349-55. DOI: 10.1185/03007995.2013.825591. View

11.

ORiordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T . Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444153. DOI: 10.1128/AAC.02095-16. View

12.

Bax B, Chan P, Eggleston D, Fosberry A, Gentry D, Gorrec F . Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010; 466(7309):935-40. DOI: 10.1038/nature09197. View

13.

Tran C, Tanaka K, Yamagishi Y, Goto T, Mikamo H, Watanabe K . In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrob Agents Chemother. 2011; 55(5):2398-402. PMC: 3088197. DOI: 10.1128/AAC.01038-10. View

14.

Bassetti M, Merelli M, Temperoni C, Astilean A . New antibiotics for bad bugs: where are we?. Ann Clin Microbiol Antimicrob. 2013; 12:22. PMC: 3846448. DOI: 10.1186/1476-0711-12-22. View

15.

Rodvold K, Gotfried M, Still J, Clark K, Fernandes P . Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012; 56(10):5076-81. PMC: 3457395. DOI: 10.1128/AAC.00766-12. View

16.

Shoen C, DeStefano M, Hafkin B, Cynamon M . and Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105800. DOI: 10.1128/AAC.00493-18. View

17.

Jorgensen J, Crawford S, McElmeel M, Whitney C . Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2004; 48(2):605-7. PMC: 321520. DOI: 10.1128/AAC.48.2.605-607.2004. View

18.

Qin X, Huang H . Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther. 2014; 8:765-74. PMC: 4094567. DOI: 10.2147/DDDT.S63581. View

19.

Peppard W, Schuenke C . Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs. 2008; 9(2):210-25. View

20.

Poulakou G, Giannitsioti E, Tsiodras S . What is new in the management of skin and soft tissue infections in 2016?. Curr Opin Infect Dis. 2017; 30(2):158-171. DOI: 10.1097/QCO.0000000000000360. View